(NYSE:DOCS)
Oppenheimer Initiates Coverage On Caribou Biosciences with Outperform Rating, Announces Price Target of $36
Oppenheimer analyst Mark Breidenbach initiates coverage on Caribou Biosciences (NASDAQ:CRBU) with a Outperform rating and announces Price Target of $36.